A Case of Lethal Abdominal Compartment Syndrome due to Rapidly Expanding Ovarian Small Cell Carcinoma Pulmonary Type

Eric M. Sieloff 1, Michael Baumgartner 2, Mark Schauer 1, Brandy Shattuck 3

1. Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, USA 2. Internal Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, USA 3. Pathology, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, USA

Corresponding author: Eric M. Sieloff, martin.sieloff@med.wmich.edu

Abstract

A 53-year-old woman presented with a rapidly growing pelvic mass suspected to be endometrial cancer due to endometrial biopsy showing grade 1 endometrioid adenocarcinoma. Due to severe aortic valve stenosis, she underwent a transcatheter aortic valve replacement (TAVR) for surgical optimization for a planned total abdominal hysterectomy, bilateral salpingo-oophorectomy, and tumor debulking. She was discharged on dual antiplatelet therapy with plans for future surgery, but was readmitted with abdominal distension, constipation, and urinary retention. The pelvic mass seen on prior imaging studies had increased in size. Unanticipated asystole cardiac arrest occurred two days after readmission, which on autopsy was found to be secondary to abdominal compartment syndrome from a rapidly enlarging ovarian small cell carcinoma pulmonary type.

Introduction

Compartment syndrome occurs in a confined space, when increased pressure leads to organ dysfunction as the result of ischemia. Many surgeons are familiar with compartment syndrome in the extremities following trauma, but it can also occur in the abdomen [1]. The World Society on Abdominal Compartment Syndrome defines intra-abdominal hypertension (IAH) as an intra-abdominal pressure (IAP) greater than 12 mmHg, and abdominal compartment syndrome (ACS) as a sustained IAP greater than 20 mmHg that is associated with new organ dysfunction/failure [2].

While most cases of primary IAH result from peritonitis, pancreatitis, and inflammatory or oncologic diseases, other causes include aortic aneurysm, abdominal and retroperitoneal tumors, mechanical bowel obstruction, abdominal trauma, and ascites [3]. Secondary causes include obesity, large volume fluid resuscitation, and sepsis [4]. ACS has many systemic effects, including decreased renal and hepatic portal blood flow, resulting in decreased cardiac output and decreased lung and chest wall compliance [2].

In this case report, we discuss the unusual presentation of ACS secondary to an extremely rare gynecological malignancy, which led to our patient’s eventual demise. Early recognition and management can be crucial to reducing morbidity and mortality in cases of ACS.

Case Presentation

A 53-year-old woman presented to the emergency department with a 12-month history of menometrorrhagia and a one-week history of worsening nausea and vomiting. Her past medical history included a moderate developmental delay, severe valvular aortic stenosis, insulin-dependent diabetes mellitus, hypertension, morbid obesity, and hypothyroidism. She had no smoking history. On physical examination, the patient was 216 lbs with a BMI of 51.9 lbs/in², which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The patient was admitted, and a paracentesis removing 3 L was performed. The serum ascites albumin gradient was <1.1 g/dL with a protein level of 3.5 g/dL and an albumin of 1.90 g/dL, and ascites cytology showed no malignant cells. A CT scan of her abdomen and pelvis and a transvaginal ultrasound showed a heterogeneous mass in the pelvis, superior and to the right of the uterus measuring 17.3 x 15.9 x 11.3 cm; these radiological findings were thought to be "likely consistent with a large focus of hemorrhage/hematoma" or an undetermined malignancy. The uterus had a 10-mm endometrial stripe, the right ovary measured 5.0 x 6.8 x 3.4 cm and the left ovary measured 3.3 x 1.8 x 2.4 cm.

The patient was cognitively impaired due to developmental delay that prevented her from being able to make informed medical decisions. Due to a complicated social situation, it took nearly a week to establish her sister as her legal designated power of attorney (DPOA) that unfortunately delayed her treatment. A gynecology oncology consultant recommended an endometrial biopsy and resection of her pelvic mass by a total abdominal hysterectomy, bilateral salpingo-oophorectomy, and tumor debulking. Anesthesiology and cardiology consultants recommended cardiac optimization for this surgery, which included a TAVR procedure.

The CA-125 (cancer-antigen 125) was found to be significantly elevated at 1,357 U/mL. An endometrial tissue biopsy was performed for which a pathology review determined it to be an endometrioid adenocarcinoma, Federation of Gynecology and Obstetrics (FIGO) grade 1. A bilateral uterine artery embolization was performed to mitigate her menometrorrhagia, during which a consultant interventional radiologist noted her uterus to be hypervascular with equal blood supply from bilateral uterine arteries along with "an enlarged right ovarian artery arising from the right uterine artery supplying the enhancing portions of the previously seen large pelvic mass." This enlarged ovarian artery was also embolized. This was the first radiographic evidence that her pelvic mass may have been of ovarian origin.

Cardiology and cardiothoracic surgery performed a TAVR after a delay of several days due to scheduling issues. The patient was initiated on dual antiplatelet therapy with aspirin and clopidogrel with plans for one month of uninterrupted therapy, after which her surgery would be performed. A multidisciplinary meeting was arranged with consultants from radiology, gynecology oncology, medical oncology, and pathology for future treatment planning. It was concluded that (1) her pelvic mass most closely resembled a bulky uterine or ovarian malignancy with possible mesenteric implants, and no further biopsies were recommended due to the patient’s need for continual dual antiplatelet therapy; and (2) recommended preoperative treatment was megestrol acetate, as grade 1 endometrial adenocarcinoma is typically a hormonally responsive tumor, and the patient and her sister had chosen not to pursue any neoadjuvant chemotherapy. Recommendations for adjuvant chemotherapy or additional treatment would be based on final surgical pathology.

A leukocytosis is persistent throughout her admission, which was suspected to be secondary to tumor production of granulocyte colony stimulating factor (G-CSF); this has been documented in the medical literature to be associated with ovarian cancers. Her acute kidney injury resolved and her creatinine decreased to 1.18 mg/dL. Two paracenteses performed during her admission removed a total of 4 L. After a three-week hospital admission, she was discharged to a skilled nursing facility on her previous diuretic therapy, aspirin and clopidogrel for her aortic valve replacement, and megestrol acetate for her endometrial cancer with a close gynecology oncology follow-up for surgical planning.

Two days after her discharge, the patient returned to the emergency department with dyspnea, lower extremity pitting edema, worsened abdominal distension, significant constipation, and newly reported urinary retention. Her weight had increased to 240 lbs, a 24-lb increase since at her previous admission. She was afebrile with a blood pressure of 105/68 mmHg, yet tachycardic to 112 beats per minute and tachypneic to 24 respirations per minute. She appeared comfortable and was oxygenating appropriately on ambient air. Her abdomen appeared slightly more distended without any tenderness or peritoneal signs, and she denied any significant abdominal pain. She continued to have a leukocytosis of 44,000/mm$^3$ and her creatinine was 1.26 mg/dL with a hemoglobin of 8.6 g/dL; there were no other significant lab findings. There was no evidence of any active infection and her lactic acid was 1.9 mmol/L. A foley catheter was placed, and 150 mL of urine was removed. An abdominal ultrasound showed only minimal abdominal ascites (an insufficient amount for a paracentesis) with an inaccessible ascites pocket in the pelvis along with a pelvic mass that appeared larger than during previous admission, confirmed by a CT scan (Figure 1).
FIGURE 1: A rapidly growing pelvic mass, initially (A) and at readmission three weeks later (B).

Arrow: pelvic mass

Cardiology was consulted along with gynecology oncology to coordinate her surgery as soon as possible, as her new symptoms were suspected to be secondary to mass effect from her pelvic tumor.

On the second hospital day, the patient was evaluated in the morning and reported no new symptoms other than difficulty sleeping. Her vital signs had stabilized overnight, and she reported no significant abdominal pain, though she continued to be oliguric despite a urinary catheter placement. Two hours later, she suffered an asystole cardiac arrest and expired despite attempts at cardiopulmonary resuscitation.

The patient’s sister requested an autopsy to further investigate for a cause of death and the primary medical team suspected a pulmonary embolism occurred due to her sudden demise, despite having received adequate subcutaneous heparin deep vein thrombosis (DVT) prophylaxis. During the autopsy, when incising the abdomen, approximately 2 L of blood-tinged fluid was ejected under high pressure. The patient’s diaphragm was found to be displaced upwards by abdominal contents and a large pelvic mass, around which there was a focal discoloration of the bowel and mesentery suggestive of ischemia (Figure 2).
No thromboembolisms were found. The necrotic endometrium was found to be 0.1-0.5 cm in thickness and the right ovary measured 19 x 14.2 x 12 cm with a 10-cm central cavity containing 500 mL of bloody necrotic fluid; both uterine arteries were embolized in addition to an enlarged ovarian artery branching off the right uterine artery, which had resulted in this central necrosis. The left ovary was 6 x 8 x 4.2 cm. The massive right ovary was somewhat unexpected as on previous imaging it could not be clearly distinguished due to pelvic organs being so adherent and surrounded by abdominal ascites (Figure 3).
On microscopic examination, the endometrium was found to be diffusely necrotic secondary to artery embolization and tissue from the right ovary appeared as small round blue cells with hyperchromatic chromatin on microscopy, most closely resembling ovarian small cell carcinoma of the pulmonary type (OSCCPT) (Figure 4).

**FIGURE 4:** Hematoxylin and eosin (H&E) staining at ×200 showing round blue cells with hyperchromatic nuclear chromatin and mitotic figures arranged in a sheet.

With OSCCPT being a rare malignancy, at the time of this report there is no established immunohistochemical profile and the diagnosis of OSCCPT was made based on the combination of histological pattern, clinical presentation, and supportive immunohistochemical staining. It was determined that a rapidly growing OSCCPT tumor and its associated ascites had resulted in ACS causing this patient’s untimely demise.

**Discussion**

We herein present a case of lethal ACS secondary to OSCCPT, a gynecological malignancy of which only a few cases have been reported in the literature [5]. Throughout this patient’s hospital course, it was difficult to assess and interpret this patient’s abdominal exam given her obese body habitus. We did not suspect ACS as she continued to deny abdominal pain and bloating, despite the rapidly enlarging pelvic mass. Conflicting interpretations of imaging studies added to the confusion. We suspect that with a large mass in her pelvis and elevated IAPs, a positional change may have led to the complete collapse of her inferior vena cava resulting in her asystole cardiac arrest.

IAH and ACS are related entities with the former being a sustained IAP > 12 mmHg, and the latter being a sustained IAP > 20 mmHg with new organ dysfunction/failure [2]. The abdominal pressures are determined by measuring intravesical pressures using a specialized bladder catheter while a patient is laying in a horizontal position, a procedure performed only in the ICU at our institution when our patient did not warrant an ICU admission. ACS can be caused by numerous factors, most commonly abdominal surgery, major trauma, hemoperitoneum, acute pancreatitis, and massive fluid resuscitation [6]. The patient tends to be critically ill, but if alert often conveys feelings of abdominal pain and bloating. A physical exam often reveals a distended abdomen and oliguria/anuria can be present in addition to pulmonary decompensation. Emergent surgical decompression of the abdomen is the treatment of choice to relieve the increased IAP [7].

Rapidly expanding intra-abdominal malignancies are an uncommon cause of ACS, and there are only a few cases of such in medical literature. In children, these malignancies have included neuroblastomas, nephroblastomas, and immature teratomas [8,9]. In adults, these primary tumors are often gynecological in nature, primarily benign ovarian cystadenomas with additional case reports of an ovarian granulosa cell tumor and a Burkitt lymphoma of the small intestine [10-15].

Ovarian malignancies can have several unique characteristics as were demonstrated in this case: they can be...
associated with significant leukocytosis and can produce massive amounts of ascites. A review by Viau and colleagues suggests that, though uncommon, the presence of a gynecologic malignancy with a leukocytosis in the absence of infection should prompt suspicion for a phenomenon known as paraneoplastic leukemoid reaction, which is suspected to be secondary to autonomous secretion of G-CSF hematopoietic growth factor and IL-6 [16]. Evidence by Thacker and colleagues and Shameem and colleagues demonstrates that the presence of G-CSF can stimulate growth in bladder cancer cells and osteosarcoma tumors, and thus autonomous factor production in gynecological malignancies could explain such rapid expansion and leukocytosis [17,18]. Malignant ascites can be seen with ovarian cancers, suspected to be the result of tumor cells producing excessive amounts of ascites while obstructing the lymphatic drainage system. A diagnostic paracentesis can be performed in an attempt to identify malignant cells from the ascitic fluid, in addition to tissue biopsy [19]. A single center study by Krugmann and colleagues reviewed 191 cases of ovarian cancer that revealed high-grade serous papillary ovarian cancers often had malignant cells present in the ascitic fluid, while the opposite was seen with neuroendocrine tumors including small cell carcinoma of the ovary, hypercalcemic type [20].

Conclusions

We present a case of a patient with endometrial adenocarcinoma and a rapidly growing OSCCPT with malignant ascites and a paraneoplastic leukemoid reaction whose surgery was delayed in order to establish a DPOA and complete post-TAVR dual antiplatelet therapy. She was readmitted to the hospital at which time there was no clinical suspicion for ACS in the absence of abdominal pain, lactic acidosis, or any significant organ dysfunction. It was only when her post-mortem autopsy was performed that the cause of her death was established to be ACS causing her cardiac arrest to the dismay of her medical team. The patient’s outcome was affected by unfortunate delays in therapy due to the delay from her TAVR procedure being performed, the need to establish a legal DPOA, the uncertainty of diagnosis of her pelvic mass on imaging studies, and the need for 30 days of uninterrupted dual antiplatelet therapy following her TAVR before performing surgery. A high clinical index of suspicion is necessary to diagnose ACS, and this should be considered in a distended abdomen with a rapidly expanding intra-abdominal tumor.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

The authors would like to acknowledge the assistance of Dr Casey Hay, a gynecologic oncologist with the West Michigan Cancer Center for her assistance in completing this manuscript.

References

1. Anvari E, Nantsupawat N, Gard R, Raj R, Nugent K: Bladder pressure measurements in patients admitted to a medical intensive care unit. Am J Med Sci. 2015, 350:181-185. 10.1097/MAJ.0000000000000543
2. Pereira BM: Abdominal compartment syndrome and intra-abdominal hypertension. Curr Opin Crit Care. 2019, 25:688-696. 10.1097/MCC.0000000000000665
3. Reintam A, Parm P, Kittus R, Kern H, Starkopf J: Primary and secondary intra-abdominal hypertension--different impact on ICU outcome. Intensive Care Med. 2008, 34:1624-1631. 10.1007/s00134-008-1134-4
4. Popescu GA, Baca T Jr, Rad P: Abdominal compartment syndrome as a multidisciplinary challenge. A literature review. J Crit Care Med. 2018, 4:114-119. 10.2478/jccm-2018-0024
5. Kalampokas E, Sharma V, Gagliardi T, Payne F, Gurumurthy M: Primary small cell ovarian cancer of pulmonary type: a case report. Gynecol Oncol Rep. 2018, 24:10-15. 10.1016/j.gore.2018.02.003
6. Papavramidis TS, Marinis AD, Plikos I, Keisigou I, Papavramidou N: Abdominal compartment syndrome - intra-abdominal hypertension: defining, diagnosing, and managing. J Emerg Trauma Shock. 2011, 4:279-291. 10.2478/jccm-2018-0024
7. Burch JM, Moore EE, Moore FA, Francisoe R: The abdominal compartment syndrome. Surg Clin North Am. 1996, 76:833-842. 10.1016/s0039-6109(05)70483-7
8. Lode HN, Henze G, Siebert N, Ehliert K, Barthlen W: Management of tumor rupture and abdominal compartment syndrome in an infant with bilateral high risk stage 4 neuroblastoma: a case report. Medicine (Baltimore). 2019, 98:e16752. 10.1097/MD.0000000000016752
9. Li-Xiang Z, Yao-Hao W, Na L, et al.: Analysis of treatment of large abdominal malignancies in children complicated with abdominal compartment syndrome: report of six cases. Medicine (Baltimore). 2017, 96:e6705. 10.1097/MD.000000000006705
10. Sabri N, Athavale V: Abdominal compartment syndrome: a rare complication of an ovarian tumour. J Obstet Gynaecol. 2015, 35:744-745. 10.3109/014436615.2015.821970
11. Haan J, Johnson SB, Scalet T: Ovarian tumor causing abdominal compartment syndrome. J Trauma. 2007,
12. Merlrico D, Roggia G, Lombardi M, Lattanzio L, Marzaoli R, Nacchiero M: Abdominal compartment syndrome due to a giant multilobulated ovarian serous cystadenoma. Case report and review of the literature. Ann Ital Chir. 2012, 83:565-566.

13. Chao A, Chao A, Yen YS, Huang CH: Abdominal compartment syndrome secondary to ovarian mucinous cystadenoma. Obstet Gynecol. 2004, 104:1180-1182. 10.1097/01.AOG.0000128106.96565.8b

14. Ng ZQ, Pradhan S, Wijesuriya R: Dilemma of the giant abdominal cyst. BMJ Case Rep. 2019, 12:bcr-2018-227255. 10.1136/bcr-2018-227255

15. Egyed E, Heiss MM, Wappler F, Sakka SG: Successful treatment of abdominal compartment syndrome with chemotherapy in a patient with a newly diagnosed Burkitt lymphoma. J Crit Care. 2019, 51:26-28. 10.1016/j.jcrc.2019.01.021

16. Viau M, Renaud MC, Gregoire J, Sebastianelli A, Plante M: Paraneoplastic syndromes associated with gynecological cancers: a systematic review. Gynecol Oncol. 2017, 146:661-671. 10.1016/j.ygyno.2017.06.025

17. Shameem IA, Kurisu H, Matsuyma H, Shimabukuro T, Naito K: Direct and indirect effects of recombinant human granulocyte-colony stimulating factor on in vitro colony formation of human bladder cancer cells. Cancer Immunol Immunother. 1994, 38:553-557. 10.1007/BF01517265

18. Thacker JD, Dedhar S, Hogge DE: The effect of GM-CSF and G-CSF on the growth of human osteosarcoma cells in vitro and in vivo. Int J Cancer. 1994, 56:236-243. 10.1002/ijc.2910560216

19. Cohen M, Petignat P: The bright side of ascites in ovarian cancer. Cell Cycle. 2014, 15:2319. 10.4161/cc.29951

20. Krugmann J, Schwarz CL, Melcher B, et al.: Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015. Arch Gynecol Obstet. 2019, 299:515-523. 10.1007/s00404-018-4952-9